Amplification of HER2 has been associated with poor prognosis in various tumor types such as advanced breast cancer, gastric cancers, colorectal and gastroesophageal junction adenocarcinomas, and non‐small‐cell lung cancer.93 The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.